Mitsubishi Tanabe Pharma Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mitsubishi Tanabe Pharma Corporation
Experts in drug development, clinical care and digital therapeutics discuss gaps in the treatment landscape for Alzheimer’s disease, as well as opportunities for prevention and innovation in care delivery.
Also, Atlas Venture and Advent France Biotechnology raise new venture capital funds, Corium secures $235m in debt to commercialize ADHD drug and CBMG leads recent VC financings with $120m series A round.
The pathway is used to clear class I and II products that don’t have a predicate device, including many innovative technologies. The original draft rule came out in 2018.
Private Company Edition: Jeito says its new first fund is Europe’s largest life science-focused fund. Illumina will use its venture capital to support tools, diagnostics, therapeutics and more. Also, IASO closed a $108m series C round and Amolyt raised $80m in series C financing.
- Drug Delivery
- OTC, Consumer
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- BIXEN Corporation
- Medicago Inc.
- Mitsubishi Tanabe Pharma America, Inc. (MTPA)
- Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA)
- Mitsubishi Tanabe Pharma Singapore Pte. Ltd.
- NeuroDerm, Ltd. (NDRM)
- PT Mitsubishi Tanabe Pharma Indonesia
- Mitsubishi Tanabe Pharma (Thailand)
- MT Pharma Singapore PTE. Ltd.
- Tai Tien Pharmaceuticals Co., Ltd.
- Tanabe Research Laboratories U.S.A.